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Abstract Established in 2008, the National Cardio-
vascular Homograft Bank (NCHB) has been instrumen-
tal in creating an available supply of cardiovascular
tissues for implantation in Singapore. This article
introduces its collaboration with Singapore General
Hospital Skin Bank Unit. The procedure of homograft
recovery, processing, cryopreservation and quality
assurance are presented. Since its establishment, the
NCHB has followed the guidelines set by the Ministry of
Health Singapore and the American Association of
Tissue Banks. A total of 57 homografts had been
recovered and 40 homografts were determined to be
suitable for clinical use. The most significant reasons for
non-clinical use are positive microbiological culture or
unsuitable graft condition. Crucial findings prompted
reviews and implementation of new procedures to
improve the safety of homograft recipients. These
include (1) a change in antibiotic decontamination
regime from penicillin and streptomycin to amikacin
and vancomycin after a review and (2) mandating
histopathogical examination since the discovery of
cardiac sarcoidosis in a previously undiagnosed donor.
Further, the NCHB also routinely performs dengue virus
screening, for donors suspected of dengue infection.
Cultural factors which affect the donation rate are also
briefly explored. By 2010, 31 homografts had been
implanted into recipients with congenital or acquired
heart valve conditions. More than half of these recipients
were children. Post-operative outcomes had been
encouraging, with no report of adverse events attributed
to implanted homografts.
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Introduction
Human heart valves have been used in surgical
procedures for the past 50 years. Gordon Murray from
Toronto reported the use of the first fresh aortic valve
in 1956 (Murray 1956). In 1962, Donald Ross (1962)
and Brian Barret-Boyes (1964; Bruce C. Paton 1992)
had independently performed the first homograft
implantation for their patients in London and Auck-
land respectively. In Singapore, the first human heart
valve was implanted by Donald Ross and Ong Kim
Kiat in 1985 (personal communication—Dr Ong Kim
Kiat).
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The first human heart valves were disinfected using
chemical agents such as formaldehyde, glutaldehyde,
beta propriolactone, ethylene oxide or high dose of
antibiotics. Subsequently, prosthetic heart valves were
introduced and used in the 1960s before xenografts
came into existence in the 1970s (Parker 2010).
However, due to the poor clinical durability and cell
viability of chemically-treated homografts, this had
led to a wane in interest in the use of such homografts
for implantation (Gall et al. 1995), until low-dose
antibiotic decontamination followed by cryopreserva-
tion and storage of homografts in liquid nitrogen was
introduced.
Antibiotic-disinfected human heart valves are the
replacement of choice in right ventricular outflow tract
reconstructions and complex left ventricular outflow
tract reconstructions in children and adults. It is also
the first choice for replacements in patients with small
aortic roots or aortic root endocarditis or patients
requiring aortoventriculoplasties. Finally, it is the
preferred alternative to prosthetic and bioprosthetic
valves for patients where long-term post-operative
anticoagulation therapy is contraindicated (Leeming
et al. 2005), children, women of child-bearing age and
adults with physically demanding occupations. The
advantages of human heart valves include excellent
haemodynamic performance, low thromboembolic
rates without anticoagulation, no mechanical damage
to blood cells which may occur for prosthetic valves,
low incidence of post-operative endocarditis and
symptomatic when there is a gradual wear-out of the
valve (which is unlike the prosthetic valve which can
fail shut suddenly) (Parker 2010).
To meet the increasing demand for aortic and
pulmonary valve homografts and to reduce the over-
reliance on expensive overseas sources, Singapore’s
only cardiovascular homograft bank was established.
The NCHB is located in a separate processing
laboratory within the Singapore General Hospital
(SGH) Skin Bank Unit (SBU)’s facility, as similar
technologies are utilised for the processing and storage
of skin and cardiovascular tissues. Furthermore, the
donation of skin and cardiovascular homograft are
governed by Medical (Therapy, Education and
Research) Act (MTERA). This co-location has led to
a greater synergy and better manpower sharing
between the two tissue banks and has brought about
a further development of a more conducive tissue
banking environment in Singapore.
In this review, we present our methods of donor
selection, recovery, processing, storage and quality
assurance of the cardiovascular homografts. In the
initial startup, the NCHB sought advice from QHVB, a
heart valve bank that was established in 1969
(personal communication—Lisa Sparks, QHVB),
and American Association of Tissue Banks (AATB).
Methods
Criteria for donors
The NCHB’s potential donors are aged between 3 and
65 years old. They belong to either one of the
following categories: (1) tissue pledgers, (2) consent
from the next-of-kin for brain dead and cardiac death
donors or (3) explanted hearts from heart transplant
recipients, whose valves are tested to be in working
condition.
Recovery of heart valve block
When a potential donor is identified, the recovery team
is activated and arrangement for a suitable recovery
site occurs. To minimise the risk of microbial
contamination to the tissues, cardiovascular tissue
recovery shall be (1) the exclusive activity that takes
place in the recovery site (either a hospital’s operating
theatre (OT) or a clean designated environment) at any
one time and (2) completed within 15 h of cardiac
death, if the donor is not refrigerated, and within 24 h,
if refrigerated within 12 h (AATB, 12th edition).
Median sternotomy is performed with care not to
enter the donor’s trachea or abdominal cavity which
will contaminate the heart. A heart valve block,
comprising of the aortic valve, pulmonary valve and
the mitral valve leaflet is excised from the heart. The
tissues are maintained in 1–10 C saline for the entire
dissection and transportation to the NCHB laboratory
for maintenance of cell viability.
Dissection, trimming and measurement of heart
valves
Once the heart valve block reaches the laboratory, it is
further separated into the aortic and pulmonary valves.
This takes place under sterile conditions in the
International Organisation for Standardisation (ISO)
188 Cell Tissue Bank (2013) 14:187–194
123
Class 5 certified laminar flow hood in an ISO Class 7
clean room. The tissue is kept moist in cold saline at
temperature 1–10 C to ensure the valve leaflets do not
dehydrate during the entire dissection (Gall et al.
1995).
The valve annulus and length of conduit are
measured. Coronary arteries are tied and ligated. The
quality of homograft is evaluated prior to antibiotic
decontamination. After recovery, competency of both
the aortic and pulmonary valves is performed by
flushing saline, with the help of a syringe, through the
valves. The valve is deemed competent when there is
neither leakage through the valves nor regurgitation as
valve leaflets inflate.
For evaluation of valve quality, visual inspection
for the presence of trauma, calcification, fenestration
in the valves and the presence of atheroma and
calcified deposits in the aortic wall is performed.
Finally, the valve is evaluated and classified into one
of the three categories (1) homografts with no visible
abnormalities, (2) homografts with some imperfec-
tions but still acceptable or (3) non-clinical homo-
grafts (AATB, 12th edition).
Antibiotic decontamination
From 2008 to 2009, recovered heart valves were
decontaminated with the antibiotic cocktail of peni-
cillin and streptomycin dissolved in Medium 199
(M199). Both aortic and the pulmonary valves were
separately incubated at 37 C for 6–12 h.
Since 2010, homografts are incubated in 100 lg/ml
amikacin and 50 lg/ml vancomycin dissolved in
M199, at 4 C for 24–28 h.
Cryopreservation
After antibiotic decontamination, the homografts are
packaged under sterile conditions in the ISO Class 5
certified laminar flow hood in an ISO Class 7 clean
room.
The homograft is then immersed in the freeze
solution comprising of 10 % dimethyl sulphoxide
(DMSO) in M199. DMSO penetrates the cellular
membrane and prevents intracellular ice crystal
formation that damages the tissue. Finally, the homo-
graft and the freeze solution is packaged in double
layers of transparent cryogenic bag and sealed
together with the completed label insert. The packaged
homograft is subsequently refrigerated, as DMSO is
toxic to cells above 10 C.
To monitor temperature changes that occur in the
processed homograft, controlled rate freezing is
performed using a controlled rate freezer in liquid
nitrogen vapour, according to an electronically mon-
itored profile. The rate of cooling is approximately
-1 C per minute. The homograft is then transferred
to a quarantine liquid nitrogen storage tank when the
temperature probe of the controlled rate freezing
reaches -50 C.
Infectious diseases and microbiological testing
A cardiovascular donor is deemed unsuitable and the
homografts discarded if any of the results for trans-
missible diseases, with the exception of venereal
disease research laboratory (VDRL) test, is positive. A
confirmatory treponema pallidum haemagglutination
test is performed if the VDRL is reactive. The test for
core total antibodies to hepatitis B antigen (anti-HBc
total) is also mandatory. An additional test for
hepatitis B surface antibodies (anti-HBs) is performed
if the anti-HBc total turns out to be positive. The
acceptable anti-HBs level is 10 miu/ml or above.
Screening for Human T-Lymphotrophic virus
(HTLV), a retrovirus that is associated with T-cell
lymphoid malignancies in adults, used to be manda-
tory for all cardiovascular homograft donors from
2008 to 2009. However, since 2010, mandatory
serology screening for HTLV-I and II antibodies
(anti-HTLV-I and II) is no longer performed. In
addition, the following tests are also performed for
donors who are suspected to have been infected, due to
their prevalence in Southeast Asia: (1) Dengue
flavivirus test using the real-time polymerase chain
reaction method and (2) Mycobacterium tuberculosis
test using acid-fast bacillus smear.
Microbiological cultures detect contamination by
aerobes, anaerobes and fungus on the tissue and
solution specimens post-recovery before antibiotic
incubation and post-incubation prior to cryopreserva-
tion. This ensures that the NCHB releases only
culture-negative homografts to the recipients.
Histopathological examination
At the time of recovery of the cardiovascular
homografts, samples of the atrial and ventricular
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myocardium, aorta and pulmonary artery are taken for
routine histological examination. The tissue is rou-
tinely fixed and preserved in 10 % buffered formalin
and wax embedment. Histological sections are at 5
microns and routinely stained with hematoxylin and
eosin, Masson’s Trichrome for connective tissue and
van Gieson technique for elastic tissue. The sections
are examined by a trained pathologist for the presence
of pathological conditions such as cystic medial
degeneration or laminar necrosis of the aorta, cardiac
muscle ischaemia and cardiomyopathy, presence and
degree of inflammation and other clinically significant
pathological feature.
Quality assurance
For the safety of recipients, cryopreserved homografts
are placed under quarantine until all the infectious
diseases, microbiological and histopathological
results confirm their clinical suitability. The NCHB’s
quality assurance staff checks and verifies the results
and donor records before submitting them for final
review by the Medical Director.
After review, clinically suitable homografts are
transferred to a clinical liquid nitrogen storage tank
and made available for implantation. Cryopreserved
homografts can be kept in liquid nitrogen for 5 years.
Homografts that are clinically unsuitable are either
stored in the quarantine liquid nitrogen storage tank
for future research or discarded should there be non-
consent for usage in research purpose.
Thawing procedure
Homograft selected by the implant surgeon is trans-
ported to the OT of the implant hospital in a charged
dry shipper at temperature below -135 C.
In the OT, the homograft is thawed in saline that is
warmed to approximately 37–42 C. After it is
completely thawed, a circulating nurse cuts the outer
freezing bag. The scrub nurse then removes the sterile
inner freezing bag containing the homograft. Subse-
quently, the homograft is rinsed in Lactated Ringers
solution for 15 min to wash off the antibiotics and
DMSO residues. This is a measure to reduce the
potential of an allergic reaction due to antibiotics and
DMSO residues when the homograft is implanted into
a patient (Leeming et al. 2005).
Post-thaw tissue and solution microbiological cul-
tures are the final step of quality assurance to verify
that the homograft implanted into the recipient
remains free from contamination. If the post-thaw
result is positive, the homograft implant surgeon is
notified immediately so that a prompt follow-up on his
patient can be performed.
Follow-up on homograft recipients
Regular follow-ups on the recipients are performed at
3 days, 3 months, 6 months, 1, 2, 3, 4 years and
finally, 5 years post-implantation of the homografts.
The following information is obtained—the reci-
pient’s current state of health, adverse reactions
caused by homograft implant, the details of homograft
explant, complications post-implant, further surgeries
performed or scheduled and the previous and next
check-up dates with the implant hospitals.
Results
Between 2008 and 2010, the NCHB recovered 57
cardiovascular homografts (aortic, pulmonary, mitral
and tricuspid valves, ascending and descending aorta
and pulmonary patches) from 28 donors (Table 1). 40
homografts (70.2 %) were ultimately determined to be
suitable for clinical use. The most significant reasons
that caused unsuitability of homografts for clinical use
were due to positive microbiological culture or
unsuitable condition of the homografts such as regur-
gitation (Table 2).
Among the 36 cardiovascular homografts that were
decontaminated with penicillin and streptomycin, 5
homografts (13.9 %) were initially tested positive for
microbiological culture post-recovery. Eventually, in
post-incubation culture, 2 were tested positive for
bacterial culture and 1 was positive for fungal culture.
Table 1 Type of donors from 2008 to 2010




Brain death—multi-organ donors 10 35.7
Cardiac death 8 28.6
Live donor—explanted heart 10 35.7
Total 28 (100)
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In addition, a homograft was tested to be positive for
MRSA in the post-recovery tissue culture but it was
negative in the post-incubation culture. However, as
penicillin and streptomycin are ineffective agents
against MRSA, the homograft was discarded for the
safety of recipients. This prompted a review in the
effectiveness of penicillin and streptomycin against
our local microflora. The SGH’s infectious diseases
physicians were consulted and the use of amikacin and
vancomycin for decontamination was subsequently
proposed. The new antibiotic regime was imple-
mented in 2010 after extensive validation studies were
performed. Besides MRSA, the presence of Clostrid-
ium, Streptococcus pyogenes, other multi-resistant
bacteria and fungus at any stage will also warrant the
discard of a homograft. For the 21 homografts
decontaminated with amikacin and vancomycin, 9
homografts (42.9 %) were tested positive for micro-
biological culture post-recovery and no homograft was
tested positive for bacterial culture after antibiotic
decontamination. A homograft was tested positive for
fungal culture (Table 3).
A significant observation is there was a higher
incidence of positive microbiological tissue and
solution culture post-recovery for homografts recov-
ered from cardiac death donors (50 %), followed by
brain dead multi-organ donors (37.5 %) and heart
transplant recipients (12.5 %).
Of the 57 cardiovascular homografts that were
determined to be suitable for clinical use, 31 were
released for implant to 30 recipients from different
restructured and private hospitals in Singapore. Most
of the homografts released were aortic and pulmonary
valves, which were in extremely high demand
amongst cardiac surgeons. The low number of homo-
graft release is primarily limited by a shortage of these
two types of valves.
A local and foreign waiting list was also imple-
mented in July 2009. This waiting list facilitates a
more systematic release of homografts, ensuring first-
come-first-release of available homografts and a pri-
ority in allocation for Singaporeans. However, in rare
cases of clinical urgency, the NCHB Medical Director
will decide on the release of reserved homografts.
There has been a rise in the number of recipients
waiting for a homograft implant on the waiting list.
This could be attributed to an increase in awareness
among cardiac surgeons that a local source of homo-
grafts is available.
Among the recipients who received the NCHB’s
homografts, 53.3 % were paediatric recipients below
the age of 18 years and 40 % were adults who suffered
from congenital heart diseases. The remaining 6.7 %
were adults who underwent operation due to infective
Table 2 Reasons for unsuitablity of homografts for implan-
tation from 2008 to 2010







Technical error during separation
of heart valve block
1 5.9
Unsuitable condition of homograft
such as regurgitation
5 29.4
Positive serology 4 23.5
Failed microbiological culture 5 29.4
Total 17 (100)
Table 3 Type of micro-organisms isolated in the microbio-

































a Refers to fungus
b Refers to bacteria, which when isolated at any stages of
processing, will have to be discarded. These micro-organisms
were MRSA, Clostridium species, S. pyogenes and multi-
resistant bacteria
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endocarditis (Table 4). Till date, follow-up of 30
recipients have been performed.
Discussion
Since the start of the NCHB’s operation, it has been
facing a chronic shortage of tissues. This is due to
several reasons.
Firstly, the invasiveness of recovery surgery and
deep-rooted cultural beliefs result in many non-
consent from next-of-kin of deceased donors. The
Asian religious and cultural beliefs in afterlife con-
tribute to many non-consent, as relatives do not want
the deceased to be without an intact body in the
netherworld (Chua et al. 2007). Moreover, it is not in
the Asian culture to discuss about the topic of death
with their family members, as it is regarded as
inauspicious. As a result, it is not uncommon for the
relatives to be unaware of the decision of whether their
deceased loved ones wish to donate their organs/
tissues upon death. Relatives’ uncertainties, together
with the additional time frame required for the
recovery of homografts, the next-of-kin would usually
not consent for donation of their deceased loved ones’
tissues.
In Singapore, the donation of cardiovascular homo-
graft is covered by MTERA. Unlike Human Organ
Transplant Act (HOTA) which mandates the donation
of heart, liver, kidney and corneas for all Singaporeans
and Singapore Permanent Residents (PR) age 21 years
and above unless one opts-out from the act, MTERA is
the voluntary donation of other organs/tissues for
anyone regardless of nationality and who is 18 years
old and above. There are two ways a MTERA opt-in
consent are obtained: (1) an individual, aged 18 years
and above, signs a pledge form or (2) consent from
next-of-kin of a donor who had not pledged his organs/
tissues under MTERA before passing away. Currently,
consent obtained through next-of-kin of donors is
significantly higher than from tissue pledgers. Surveys
performed by the NCHB, during public awareness
events, revealed that most members of public were
unaware of the existence of MTERA and had a
misconception that heart valve donation was covered
under HOTA. As a result, many people did not
actively make a decision to pledge the donation of
their cardiovascular tissues. Therefore, to increase the
overall donation rate in Singapore in the long term,
consistent efforts in public education, especially in
reaching out to the young generation and dispelling a
common misconception by reinforcing that heart
valve donation is under MTERA and not HOTA, is
necessary. However, this will take a number of years,
probably even a generation or more, before any
increase in consent rate or number of pledgers can be
observed.
Secondly, some homografts were discarded as a
result of contamination during recovery. A significant
observation for the highest incidence of positive
microbiological tissue and solution culture post-
recovery for homografts from cardiac death donors
are largely due to a difference in recovery sites. Data
revealed that recovery performed in non-OT clean
environment for cardiac death donors, resulted in a
higher post-recovery contamination rate of 62.5 %. In
contrast, both the recovery for brain-death multi-organ
donors and the heart transplant patients are performed
in the OTs. Nonetheless, despite tissue recovery being
performed in the OTs, the incidence of contamination
post-recovery remains significantly higher for homo-
grafts recovered from multi-organ donors (37.5 %), as
compared to heart transplant patients (12.5 %). This
lower post-recovery contamination rate in homografts
recovered from heart transplant patients can be
explained by several reasons: (1) a shorter exposure
time to the OT environment, (2) the complete isolation
of thoracic cavity from abdominal cavity during heart
transplantation (Gall et al. 1995; Tabaku et al. 2004),
Table 4 Clinical diagnosis of the NCHB recipients from 2008
to 2010
Diagnosis of recipients No. of
recipients
Congenital
Tetralogy of fallot 6
Congenitally corrected transposition of the great
arteries
1
Transposition of the great arteries 1
Pulmonary atresia with ventricular septal defect 6
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(3) an absence of the inherent problem of contamina-
tion caused by microbial migration from the gastro-
intestinal tract through the bloodstream to the heart
valves after death (Gall et al. 1995) and (4) a shorter
hospitalization stay prior to tissue recovery.
Thirdly, some homografts are tested to be unsuit-
able after a stringent screening process. According to
the AATB’s recommendation, after 11 November
2009, screening for anti-HTLV-I & II was no longer
mandatory for all cardiovascular homograft donors, as
it is a non-leukocyte-rich tissue. Because of this,
testing shall be determined by the Medical Director
(AATB, 12th edition). Hence, since 2010, the NCHB
ceased its mandatory screening. Furthermore, it is
noteworthy that the incidence of HTLV infection
follows a unique geographical and ethnic distribution
(Wang et al. 1991), in which Singapore does not fall
within the HTLV-endemic region (Zhao et al. 1991).
In addition, screening for anti-HTLV-I and II was not
performed for solid organ donors in Singapore.
The NCHB performs two tests which are not
commonly performed in other tissue banks. The first
test is for detection of dengue virus, which is
transmitted by flavivirus-infected Aedes mosquitoes.
It is a mandatory test for all donors who manifest
symptoms of dengue infection. This is because dengue
infection, which causes dengue fever, dengue haem-
orrhagic fever or dengue shock syndrome, is endemic
in many parts of Southeast Asia, including Singapore.
The high prevalence in dengue seropositivity among
the adult population in Singapore was revealed
through a study conducted by Wilder-Smith et al. that
45 % of the adults had positive dengue serology
(Wilder-Smith et al. 2004).
In solid organ transplantation, the transmission of
dengue infection from donor to recipient can result in a
loss of the allograft and even death of the recipient in
severe cases. The occurrence of dengue virus infection
in an immunocompromised transplant recipient can
have detrimental effects, the most life-threatening of
these being the development of dengue shock syn-
drome. (Tan et al. 2005). It was first reported in 2004
that two renal transplant patients passed away after
each of them received a kidney from a donor who was
infected by the dengue virus. Both patients eventually
developed complications and died of multi-organ
failure within weeks after their transplantation. (Ng
and Chan 2010). Therefore learning from this expe-
rience, the NCHB takes precaution by screening all
cardiovascular homograft donors who manifest any
one of the signs of suspected dengue infection: (1)
prolonged prothrombin time or partial thromboplastin
time which indicates an abnormality in the coagulation
pathways, (2) low platelet count of below 140 9 109
or (3) platelet count falls below 25 % of their own
normal baseline, which is between the range of
140 9 109–440 9 109.
The second test is histopathological examination of
the donor heart. Before December 2008, mandatory
histopathological examination was not performed on
recovered tissues. Only the results of histopathological
examination on explanted hearts, which was the
hospital’s routine test for heart recipients, were
evaluated. Subsequently, this procedure was reviewed
when one of the explanted hearts was diagnosed with
granulomatous myocarditis, with features suggestive
of cardiac sarcoidosis. Cardiac sarcoidosis is a rare but
potentially fatal condition of unknown etiology that
has been reported to occur in isolation without
evidence of sarcoidosis in other parts of the body.
Sarcoid granuloma may involve any location in the
heart, including the myocardium, endocardium and
valve leaflets leading to regurgitation (Kim et al.
2009). The principal sequelae includes conduction
abnormalities, arrhythmias, heart failure and even
sudden death (Ayyala et al. 2008). A study in Japan
revealed the mortality related to cardiac sarcoidosis
was discovered in 46.9 % of sarcoidosis-related
deaths. However, clinical diagnosis had only been
made in 26.7 % of the cases (Iwai et al. 1993),
revealing the disease’s variable clinical manifestation
(Kim et al. 2009). Therefore, since 2009, mandatory
histopathological examination is implemented in the
NCHB. Further, we also recommend all cardiovascu-
lar tissue banks to consider performing this examina-
tion. The benefits for histopathogical examination of
the heart tissues include the identification of any
potentially inherited or undetected heart condition that
will compromise valve quality and eventually, on the
recipient’s health.
The ultimate objective of a reliable cardiovascular
bank should not solely focus on increasing the number
of donors and cardiovascular tissues recovered. More
importantly, there must be a stringent quality assur-
ance programme in place, which should be constantly
reviewed, to ensure that the homografts recovered,
processed and stored, are safe for the recipients who
require them.
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